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WmberS of Pts from each region and (heir characteristics are Shown m the 
table. Although selection brases affect the ‘ypes of PCs entered tn a clinical 
trial, these data Indicate that while the enro d SMF Pts are simils in many ot 
these regions. several potenlially important diIferencffS exist (etiology of CHF, 
prevalence of hypenens!on and diabetes. use of CABG). Such differences 
may impact on results applicablllty of trials conducted In single countries or 
regions. 
1044-30 Large Dlffarences In bug l’kaatment of Chronic 
Heart Fallure Between the EurOPean Cauntrlae 
D.J. van Veldhulssn, A. Charlesworth’. JR. Hampton’. H.J.G.M. Crijns. 
&?~1. Of Car&o/w UncverS@ HoS~11al Gmnirqen, 7he Nether/erx& 
‘Nartingham Clinical Rial DaIa Centre. UK; “Oueerr$ Me&al Centre, 
UniverWy Hospiral Nottingham UK 
Congestive heart failure (CMF) is charactmized by a high morbidity and 
modality. Although a large number 01 drugs am cunenIIy used in CHF, the 
use of these various agents is not unifon. In order IO examine treatment 
palterns for CHF between countries. we examined drug use m patients (pts~ 
who were part of the PRIME-II Trial (lbopamine Survival Study). A total of 
1806 NYHA ctass lit-IVpts were randomized from 199210 1996. AlIhough 13 
European countries participated, we only examined countries who included 
GO pts. leaving a study population of 1625 pts from 9 countries. At baseline. 
pls had an ACE-inhibitor (unless intolerant = 8%) and diurekcs. (data are 
% pts on class of drugJ.(NL = Netherlands, UK = llnited Kingdom. GER = 
Germany. IT = Italy. FR = France, BE.Belgium, SP = Spain. SW 5 SwiIzeriand. 
OK = Denmark). 
NL UK GER IT m BE SP SW OK 
no. pts 427 337 223 220 208 124 123 62 61 
dtgllalls 60 39 67 81 56 62 71 65 77 
lull-dose ACEmh’ 25 35 16 19 22 17 32 29 25 
an%anhythmcs 16 23 19 25 44 26 16 32 15 
bet+blockers 11 2 10 3 3 10 3 6 7 
ca.bloCkerg 7 t* 13 5 15 2 5 1 9 
anllcoagulanls 70 39 42 2: 19 23 47 66 31 
an\lplaWtels 18 43 32 24 26 32 31 23 5.1 
t 3 . 50 mg edptopnl. 2 . 20 mg enalapnl or eqwaxn. 2 * 90% ammdarone 
C0ncrusion.s: large differences in drug use for patients with moderate 
to severe CHF are observed between (European) countries. Whether this 
is related IO factors such as tradition. economic/financial circumstances. 
national guidelines. etc. is unknown. but this issue needs further study. 
[ 1044-31 1 Reduced HospitalizMions and Health Care Casts 
by an Interactive Home Monitoring Program for 
Heart Failure Patients 
P.A. Heidenreich, C. Ruggerio. B.M. Massie. Star&u’ University Sian&d, 
CA and University of Califomfa. San Francisco, CA, USA 
Chronic heart failure is associated with frequent hospitalizations and high 
resource use. This study examined the effect of a multidimensional program 
of patient (pt.) educalion. monitoring, and physician nolification on medical 
costs and hospilali:atons. 68 ptS. of a community-based medical group with 
heart failure. (NYHA class Z-4) were enrolled. Each patient (me- age 73 * 
5 yrs., 59% male) received an electronic BP cuff. digital scale, and weekly 
educational mailings. Palients were contacted weekly by a nurse to evaluate 
clinical status. Vital signs, weight. and Symptoms were recorded dally using 
a computerized phone system. Physicians were notified by fax of abnormal 
Vital Signs, SymptOmS, or weight Changes. During ‘12 f- 5 mos. Of tOtlOW-Up 
284 MD notifications occurred for 53 pts.; 42% of notifications were followed 
by an intervention (medication change 39% or clinic visit 24%) Within 14 
days. Program patients with claims data from 1995 (N = 43) were matched 
(based on gender, age, and 1996 claims) to 66 heart failure pafienls who 
were not enrolled. Medical claims, log (claims), admissions. and hospital 
days in 1996 were reduced for patients in the program (Table). The program 
was rated good or excellent by 97% 01 pts. In summary. this sway s~ggost~ 
that a mUlIiUimenSiOna1 monilonng program for pallents with hearc la&lure ten 
reduce hospltalizatlons and medical costs. 
Group N 
Program 43 
Contra1 86 
’ F .I 0.05 
iIzl 1044 32 Shurt-term Outcomea and In-ttospltaf ~erource UWatlon In Heart Fnllure: A Comparison of 
Syfftollc Verwr Olaatollc Dyafunctlon 
K.J. HarM. T. Tutgut. M. Shah, JS. tiumphde, J. Newman, J. Cheint. 
H. Ventura, F. Smelt. Ochsner M&Scat IrWluflons, New Orleans. Louisiana, 
USA 
Background: The #feel 01 loft ventricular ejsctlon Irccctlon (LvEF) on short. 
term clinical outcomes and resource utilixatlon during hospitalization for head 
failure has not bean evaluated. 
Melhods: In d43 consecutive hospitalizations for heart failure tn patients 
with known LVEF, we compared mhospltal and 30&y mor18111y, 30+ 
readmisslon rates, hospltallzatlon cost. and length of stay between patients 
with systolic dysfunction (LVEF 5 40%; Group I: n = 266) versus those with 
diastolic dysfunction (LVEF > 40%; Group II: n I 157). 
ReSuRS: Patients with Systolic dySfuncIion were younger (69 vs 73 yean: 
p = O.OOl), less likely to be white (59% vs 73%. p s 0.007). and tended to 
be male mure often (68% vs 49%: p = 0.08) compared IO tie wiIh diastolic 
dysfunction. They were less likely IO have atria1 fibrillation (309’. vs 44%; p z 
0.002). but equally likely lo have hypertension and coronary artery disease. 
Shart.term oulcomes and resource ullllzatlon. expressed per hospitalization. 
are shawn below: 
Length of stay (day9 4.0 37 003 
Wosplsl!zatlan co$ts f US S) 3.016 2.825 0.06 
In-hospitatmmtality 2 596 2.6% NS 
3OdaY moIlaMY 4.0% 4 6% NS 
-“May readmrsstons (any cause) 0.39 025 005 
3Oday readmwons (heart tatlure) 022 0 11 0.01 
Munmle readmlssvxt6v 6.lZ 2 1% 001 
c~nC~u,Yiorts; Followmg hospilalrzation tor heari fa!lure. parents wrth mod. 
emI@ or severe left ventncular dysfunc!Km have greater resource ut!llratlon 
and readmissions. buI similar short-term monakty compared IO patlen& wl!h 
mild or no systolic dystunction. 
1-I 1044 33 Gender Biab in the Medical Management of Heart Failure: The Cardiologist Versus the 
Non-Cardiologist 
K.J. Haiai, E. Nunez. J.S. Humphne. T. furgut. J. Newman. Ochsner 
Me&el Instibrriuns. New Orleans. Louisiana. USA 
Backgtuund; The purpose of this study was to assess if gender bias exists in 
the r.lanagement of heart failure (HF). and to evaluate its relation to ceregiver 
specialty (cardldogist vs non-cardiologist). 
Methods: In 309 consecutive hospitalizations for HF in 216 pts (66 f 14 
yrs: 61% male) with LV ejection fraction _ ~453’0. we examined the relation of 
pt gender with uliiization of lhe followIn<; medications at lhe time of hospdai 
discharge: vasodilalors. diuretics, cligoxin. and combined therapy (COMB, 
i.e. vasodilator + diuretic + cligoxin). Using clinical data, we devetoped mul, 
tiple logistic regr@$sion models to predict the likekhood that pts would be 
discharged from the hospital on treatment with these medications. pt gender 
and caregiver speciaky were forced into the models. 
ResulIs: The Irequencies of use cf vasodilators. diuretics. UIgoxin. and 
COMB at Ihe time of &charge were 66. 92. 77. and 66% respectively. PI 
gender was not assoctated wilh use 0. _ 1 POME in univariate or multtvariate 
analyses. However, the interaction term ot gender and CaregIver specialty 
was stgnificantly associated with COMB (p = 0.01). Thus. cardtologi~s were 
more likely to employ COMB in males vs females (adjusted probability 73 yi; 
59%). while non-cdrdiologish util:;tedCOMB less often in males (46 Vs 7696). 
Similarly. cardiologists used digoxin more often in males (60 vs 73%). while 
non-cardiologists used it more often in femafes (55 vs 9@‘6). NO eSSociaIron 
was seen beIween gender and use of vasodilators or dlureticS. When Only 
the RrSt hospitalizations of each pt were ?nalyZed, gender a,nd caregiver 
specialty ahowed similar asS@ciat~ons with use of COME and dlgoxin. 
Conclusions: 1) pl;,snXicant differences exist cn the utd~zation of effective 
nwdiwtions in male vs fe.mafe 016 with HF: these findmgs raise the possibility 
JACC F~hnIiI~ I’J’JX 
ol gender bias in tho management ol HF; 2) Caregiver SpOCialty may lnfk~eflce 
gander blas in managoment of HF. 
I 
1044 34 Are Womon Wlth Heart Failure lkeated 
Differently? 
C.A. Sueta, A. Lulla, D. Slggs, SC. Smith Jr., R.J. Simpson Jr. Medical 
Revlow of North Carolina. Inc.: Mcm?k, Co.: Unlversify of Norfh Cflrullns. 
Chapel HI/I, NC, USA 
Sovorat studlea havo raportod dlffarancos In ths treatment 01 women with 
cardlovaaoult\r dlseaaa comparad to man. We ravlowod an admlnlatratlva 
data sat oontalnlng chall audlts an 16,576 oulpallsnts (pta) with a haart 
fallura (HF) dlagnosln from 138 US cardiology and multl~speclalty practlcas 
to dotarmlne whothor there wore gander dlffarenaaa In the uao of ACf3s. 
Pte had an ICD-9 coda 429, wore ovor lha n9a of 21 years (yra) and had at 
loaot 2 vlslts wlthln tho provlous 12 months, the last vislt occurrlng bolwoon 
7/l/95 nnd 1011199. Tho moan ago was 73 f 12 yrs and 47% were womon. 
Comparod to mon, womon wore oldor, had moro hypartanalon, 49% vs 39o.i) 
and less lachemic dlsaaae 32% va 4A%. Tho mcan LVEF dotormlnad In 
10,623 pta (94%) was algnlllcantly hlghar In wamon aamparad la man, 49% 
t- If va 39% -L 19, p m R.I)FOl. ACE.1 lhompy was pranorlbad In 46% ol 
womon vs 63% 01 mon. tlowovor, of Iho pts with nn LVEF c 4O?h, 98% al 
women vs OQO/R of men recalvad nn ACE-I. Tho recommandod tnrgot doso of 
ACE.1 was proacrlbod In 3596 of woman end 97% of man. 
Tho pmacrlptlon at ACE-Is romnlnn auboptlmnl In pts with HF. Women 
opponr to havo bollal prosolved LV lunctlon nnd mom dlaatollc dyalunctlon 
compared to man. However, In pta with an LVEF .~ 4096, ACE-I proscnptton 
and doslng appaars slmllnr In mon and woman. 
r 1044-3, The Prognostic Slgnlllcance of Valvular Abnormalities In Patlenta Wlth Severe Lafl 
Ventricular Dyafunctlan 
J.R. Teerllnk, T.S. Newman, E. Foster. N.B. Schlllar. UCSF Medlcill Confer. 
Snn Fran&o, CA, USA 
Backgmund: Loll vontrlcular dystunctlon Is an lncroaslngty common health 
problem wlth poor survival rates despite recant advances In treatment. How. 
ever, even patients with markadly reduced function have slgnllicantly dls. 
parate survlvnl. We examined the prognostic value of valvular disease In 
an unselected group 01 patients wlth systolic dysfunction (LV ejection frac. 
tlon ~35%) referrod for echocardiography between 1999-1990. excludmg 
patients with congonltal heart disease. 
Methods: Severity codes for valvular nbnormalltles were linked to a more 
talky database derived from state and national vital statistics and Cox propor. 
tional hazards models were used to measure their association with survival. 
Resub: 01 6605 patients referred for echo during this time period, 676 
patlams (moan age = 61 t 3 years; M:F 2.2.1) had LV ejeclion fraction8 
-35%: In this cohort. stgnlficant unlvarista pradtctors 01 death were aortic 
stenosis (,y’ 45. p < 0.0001: Severa AS relative hazard 3.9. C.I. 2.168) ana 
mitral annular calcification ( ts 19. p c 0.001; Savere MAC relative hazard 
2.8, Cl. 1.1-7.6). with no significant predictive value 01 mitral regurgitation 
nor mitral valve prolapse severity: there ware insufficient cases of aorlic 
msufflclency and mitral stenosis for analysis. Unexpectedly. in a multivan- 
ate modal including valvular abnormalities, ejection lraction and age, mitral 
annular calcification remained an Independent predictor along with aortic 
stenosis. 
Conclusion: Although the impact of aortic stenosis on survival is well rec- 
ognized. the age-independent effect 01 mitral annular calcilication in pationts 
with severely reduced left ventricular function is provocative, warranting lur- 
thar investigation with particular attention to the relationship between MAC 
and cerebrovascular events. 
11044_361 Do Cllnlcal Events Predict Subsequent Mode of 
Death In Patients With Advanced Chronic Heart 
Failure? 
G. Neubarg. A. Miller. C. O’Connor, Ft. Selkin. P. Carson, A. Cropp. 0. Frid. 
M. Presslor. J. Wertheimer. For the Pf?AlSE Investigators: Cofumbia 
Unrversrfy New York NY USA 
Background: Prevention of sudden death (SD) in heart failure (CHF) pts is a 
priority, but prediction of SD is difficult. Efforts to dekne SD pre Victors have 
examined baseline pt data but not interourrent events. PRAISE monitored 
nonfatal Oven18 in pts with advanced CHF over 14 months, so we evaluated 
their relation to cause-specific mortality. 
MerhO@? We compared tutal mortality (TM). SD, pump failure death (PF). 
other deaths & SDRM in 1) all pts; 2) pts with adverse events (AE) of wors- 
ening CHF; & pts with “life-threatening” events judged by an Endpoints Com- 
mittee (EC). iw ‘*lding 3) hemodyrlamic (HD) events (severe hypr?eriusion. 
pulmonary edema) 8 4) nonHD ovonts (sustained ventricular arrhythmias or 
myocardlal Infarction). 
n TM% SD”. PF% olhor% SDrrM 
1) All PRAISE pta 11% 30 1s 14 6,2 04s 
2) AECHF 451 60 15 27 80 0.30 
3) EC.HD 71 65 5.6 37 13 a.10 
4) EC.nonHD 4s 49 22 13 13 0.45 
Resulfs: Nonfatal cardiac ovonts Increased marfallty rtsk In PRAISE. 
NonHD eventa corrlacf tha most SD rlak. but SD/TM waa simllar 10 Iha 
overall population. HD ovanta carrlad the hIghost TM risk, but predlcted 
lowar lnoldanca and pmporllan al SO. 
Conclusion: SD romalns prevalent In advanced CHF, but recent HD tnsta- 
blllly strangly pradlots PF death, so HCI event-lrue pls have greater potential 
aurvlval banollt lram antI-arrhylhmlc drugsldovlces, Asaumlng davlces may 
roduco Sll by fig%, thsy would have roducod TM by 22% In group 1 but only 
by 15% In group 2. or 596 In group 3. 
iIII-3 1044-37 Decreased Left Ventricular Ralatlve Wall --_* Thlcknoas Predlcta Decreased Event-Free 
Survival In African Amerlcans With Dilated 
Cardiomyopathy 
M,Q. Koono. M.G. St. John Sutton, 0, DoNofrio, E. Lob. Universrfy of 
Rnnsylvank School ol Medicine, Phtlndolphra PA. l/S4 
Background: LV wall thtcknoss Increases to match LV cavity dtamoter. pm- 
sorvlng normal wall straas and contractila Iunction. The ratio of wall thickness 
to cavity dlametor, rolabve wall lhtcknaas (RWT). ia therefore maintamed con. 
slant In tho normal heart, Irrespoctlva of heart size. In dilated cardiomyopathy 
@CM). fallure to malntaln RWT has been aS8OCiated wlth poor prognosis in 
whites. The Impact of RWT dlffomnccs In African Americans (AA) with DCM 
has not bean studied. 
Methods: LV dimensions and RWT warn assessed on baseline echoes of 
all AA patients presenting to our hoart lailure service from 1991 to 1997. Muth- 
ple cllnlcal covarlates were assessed. obtained from a prospecllve dalabasa. 
Measured outcome was survival to a combined clinical endpoint. mcludmg 
death and cardiac transplantation. 
Resuffe: $4 AA pts (4OM. 14F) were identified, wllh mean follow-up a? 
20.1 f 16.4 mos. RWT .’ 0.3 (250 below the population mean), NYtiAclass. 
and history of hypertension (HTN) were signllicant predictors of decreased 
evenblree survival in unlvariate analyses. Pts with low RWT had a mean 
event-free survival of 13.6 + 2.2 mcnths. compared to 46.2 f 4.0 months 
in pts with normal RWT (p i 0.001). There was no correlatton between 
RWT and HTN. RWT ..0.3 ramainad a signihcant predictor (p = 0.053) m 
Cox multwariate regressIon, while NYHA class and HTN were no longer 
associated. 
Conclusion: Inappropriately low RWT independently predicts death and/or 
the neod for cardiac transplantation in AA wifh DCM. 
\1044-381 Did Cllnical Features Dlstingulsh Low From 
Normai Ejection Fraction in Chronic Heart Failure 
In the DIG Trial? 
E.F. Phllbin. S. Hunsberger. R. Garg. S. Kouz. E. Lader. U. Thadani. 
A Weeks, F. McSherry. M.A. Silver. Henry Ford Hospital Delro~t, MI. 
NHLBI. Bethesda. MD. USA 
Background: Whether cknlcal data In chronic HF distinguish pahents with a 
low vers$ normal L\1 FF is controversial. 
Methods: Hall of the patients in the DIG Trial database were randomly 
assigned to a Derivation Set, which was used to develop a linear regression 
model for EF based on medical history, physical exam and laboratory data 
kept on file. The remainder, a Vakdation Set, were used to assess this 
equation’s predictive validity. 
Resulfs: The best model (6 = 0.23, p . 0.00001, Mallow’s Cp = 24.5) 
retained these predictors: age, sex, previous MI. functional class. hyperten- 
sion. angina. systolic and diastolic SP, heart rate, body mass index, elevated 
